- Home
- TARS vs NVCR Comparison
TARS vs NVCR Comparison
Compare TARS & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARS
- NVCR
- Stock Information
- Founded
- TARS 2016
- NVCR 2000
- Country
- TARS United States
- NVCR Switzerland
- Employees
- TARS N/A
- NVCR N/A
- Industry
- TARS Medicinal Chemicals and Botanical Products
- NVCR Medical/Dental Instruments
- Sector
- TARS Health Care
- NVCR Health Care
- Exchange
- TARS Nasdaq
- NVCR Nasdaq
- Market Cap
- TARS 1.8B
- NVCR 1.9B
- IPO Year
- TARS 2020
- NVCR 2015
- Fundamental
- Price
- TARS $40.65
- NVCR $16.69
- Analyst Decision
- TARS Strong Buy
- NVCR Buy
- Analyst Count
- TARS 7
- NVCR 6
- Target Price
- TARS $67.14
- NVCR $32.83
- AVG Volume (30 Days)
- TARS 552.3K
- NVCR 1.6M
- Earning Date
- TARS 08-07-2025
- NVCR 07-24-2025
- Dividend Yield
- TARS N/A
- NVCR N/A
- EPS Growth
- TARS N/A
- NVCR N/A
- EPS
- TARS N/A
- NVCR N/A
- Revenue
- TARS $233,674,000.00
- NVCR $621,711,000.00
- Revenue This Year
- TARS $122.94
- NVCR $5.56
- Revenue Next Year
- TARS $44.14
- NVCR $9.19
- P/E Ratio
- TARS N/A
- NVCR N/A
- Revenue Growth
- TARS 449.03
- NVCR 18.27
- 52 Week Low
- TARS $20.08
- NVCR $14.17
- 52 Week High
- TARS $57.28
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- TARS 40.26
- NVCR 43.44
- Support Level
- TARS $39.25
- NVCR $17.20
- Resistance Level
- TARS $42.01
- NVCR $18.02
- Average True Range (ATR)
- TARS 1.93
- NVCR 1.04
- MACD
- TARS -0.05
- NVCR -0.09
- Stochastic Oscillator
- TARS 22.95
- NVCR 15.51
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.